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Konstantinos Stellos, MDc,e,fABSTRACTAging-related cellular and molecular processes including low-grade inflammation are major players in the pathogenesis
of cardiovascular disease (CVD) and Alzheimer’s disease (AD). Epidemiological studies report an independent interaction
between the development of dementia and the incidence of CVD in several populations, suggesting the presence of
overlapping molecular mechanisms. Accumulating experimental and clinical evidence suggests that amyloid-beta (Ab)
peptides may function as a link among aging, CVD, and AD. Aging-related vascular and cardiac deposition of Ab induces
tissue inflammation and organ dysfunction, both important components of the Alzheimer’s disease amyloid hypothesis. In
this review, the authors describe the determinants of Ab metabolism, summarize the effects of Ab on atherothrombosis
and cardiac dysfunction, discuss the clinical value of Ab1-40 in CVD prognosis and patient risk stratification, and present
the therapeutic interventions that may alter Ab metabolism in humans. (J Am Coll Cardiol 2020;75:952–67)
© 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).S everal cardiovascular risk factors have longbeen associated with a greater risk for futurecognitive decline in nondemented individuals
(1). Control of vascular risk factors effectively reduces
the incidence of dementia in both healthy and cogni-
tively impaired individuals (2). The presence of
intracerebral atherosclerotic vascular disease (3) ex-
acerbates all types of dementia and has been
independently associated with worse cognitive per-
formance even in nondemented individuals (4).
These observations indicate that the aging-related in-
flammatory nature of both atherosclerosis and de-
mentia involves multiple common cellular and
molecular mechanisms. Recent accumulating evi-
dence points toward the existence of a possible
nonexclusive shared systems biology process that
may drive aging-associated diseases, atherosclerotic
cardiovascular disease (CVD), and dementia
(Figure 1).
Production and accumulation of amyloid-beta (Ab)
peptides in the brain are considered the hallmark of
Alzheimer’s disease (AD) amyloid hypothesis (5). The
prototypic cerebrovascular disease associated with
Ab40 deposits is cerebral amyloid angiopathy (CAA)
(6). CAA describes a group of aging-associated braindisorders with characteristic pathological findings of
amyloid deposits predominantly in the arteriolar
wall. Clinical and imaging features of CAA vary from
asymptomatic microbleeds to severe hemorrhage,
neurological deficits, cognitive impairment, demen-
tia, and death. Defective perivascular drainage of
neuronal-derived Ab is probably the main mechanism
of Ab deposition. Among Ab peptides, Ab1-40 is the
main peptide involved in the pathogenesis of CAA,
whereas Ab1-42 is mainly involved in development of
AD. The vascular preference of Ab1-40 has led to the
hypothesis that this molecule may exert proin-
flammatory properties not only in cerebral but also in
peripheral vasculature, mediating arterial disease as
depicted in Figure 1, suggesting a continuum of
Ab1-40 deposits in the circulatory system ranging
from leptomeningeal and cortical cerebral microvas-
culature (CAA) to intracerebral, carotid, aortic, or
coronary vascular wall or heart. Interestingly, in
contrast to studies examining associations between
Ab1-40 plasma levels and cardiovascular disease,
studies assessing the association of plasma Ab1-40
with cognitive function have not yielded consistent
results (7). The detrimental properties of Ab1-40
species on vascular brain pathology affecting memory
HIGHLIGHTS
 Aging is the most important risk factor
for the development of cardiovascular
disease and dementia. Yet, the over-
lapping underlying mechanisms are not
completely appreciated.
 Ab, an aging-induced peptide and the
hallmark of the amyloid hypothesis of
Alzheimer’s disease, constitutes an in-
dependent cardiovascular risk factor.
 We review the determinants and the role
of Ab in cardiovascular system and
disease.
 We call for research gathering evidence
on how to treat this newly recognized
ABBR EV I A T I ON S
AND ACRONYMS
Ab = amyloid-beta
ACS = acute coronary
syndrome
AD = Alzheimer’s disease
ApoE/ = apolipoprotein
E-deficient
APP = amyloid precursor
protein
BACE = beta amyloid cleaving
enzymes
CAA = cerebral amyloid
angiopathy
CAD = coronary artery disease
CVD = cardiovascular disease
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954and cognition secondarily to microvascula-
ture damage rather than through direct
neurotoxicity, may explain this discrepancy.
In this review, we present contemporary
evidence that links Ab peptides with vascular
inflammation and a wide range of associated
extracerebral atherosclerotic manifestations
and myocardial dysfunction, as well as
adverse CVD outcomes and mortality (Central
Illustration). Based on this evidence, we
discuss the potential clinical utility of Ab1-40
as a biomarker for risk stratification for
mortality and present therapeutic in-
terventions that may alter Ab accumulation.
AMYLOID PRECURSOR PROTEIN
AND Ab METABOLISMentity.Ab peptides are proteolytic fragments of amyloid
precursor protein (APP), an integral membrane pro-
tein (8,9). The APP gene produces 3 major splice
variants (10), APP695, APP751, and APP770, produced
in neurons, endothelial cells, and platelets, respec-
tively. The exact physiological function of this well-
conserved, site-specific APP/Ab pathway is not fully
elucidated, but it is associated with natural antimi-
crobial defense (11) and coagulation cascade proteo-
lytic events (12). The latter is mediated by a Kunitz-
type serine protease inhibitor domain contained in
APP751 and APP770 molecules.
APP can be initially cleaved by a-secretases gener-
ating nonamyloidogenic products depending on its
location on plasma membrane, the site of processing
(membrane or endosomes), and environmental pH
(13), or by b-secretases, also known as beta amyloid
cleaving enzymes (BACE) (Figure 2). The b-secretase–
mediated cleavage of APP retains the integrity of Ab
fragments within the remaining C99 peptide, while
C99 subsequent cleavage by g-secretases releases Ab
peptides (14). C99 cutting site by g-secretases depends
on the location of processing (endosomes or Golgi
network) and generates amino acid peptides of length
40 (Ab1-40 mostly found in vascular lesions) and 42
(Ab1-42, mainly found in AD-associated brain lesions),
as well as the intracellular domain of APP (Figure 2).
Several factors, including aging, inflammation, renal
dysfunction, ischemia, polymorphisms, and drugs,
increase circulating levels and subsequent tissue
deposition of Ab by augmenting APP production and
processing or by decreasing Ab clearance and degra-
dation (Figure 2, Online Tables 1 to 3). Under normal
conditions an equilibrium exists between Ab produc-
tion and removal in various compartments inside
or outside of the central nervous system (15).Deregulation of this equilibrium may lead to accumu-
lation of Ab1-40 in blood, vascular wall, and heart tis-
sues, which has been associated with CVD.
SYSTEMIC ACCUMULATION OF Ab AND CVD
PERIPHERAL VASCULAR Ab ABUNDANCE. Although
APP processing in different cell types gives rise
preferentially to Ab1-40 or -42 (16), it is not known
what drives this differential final processing of the
amyloidogenic pathway of APP. In cases of CAA,
neuronal-derived Ab (either Ab1-40 or -42) fails to
drain away from the leptomeningeal vessels, capil-
laries, and brain parenchyma (17). This defective
depletion leads to its accumulation in brain arterioles.
Ab deposits are observed in the tunica media in close
proximity as well as inside of the smooth muscle cells
and in the adventitia, avoiding endothelial cells even
at higher degrees of CAA (18,19). Because impairment
of adventitial lymphatic capillaries in peripheral
vessels also aggravates atherosclerosis, the role of
lymphatic drainage in Ab-related cardiovascular dis-
ease should be further explored. In peripheral
atherosclerotic lesions, Ab deposits consist almost
exclusively from the Ab1-40 species (20). Using mass
spectrometry, Ab1-40 peptide was on average 100
times more abundant than Ab1-42 in human aortic
atherosclerotic plaques (21). The 2-peptide-amino-
acid-longer species Ab1-42, being more hydrophobic
and fibrillogenic, is the main amyloid peptide found
in parenchymal lesions of AD; however, its “vascular”
involvement is limited to deposits in pericapillary
spaces and glia limitans, parenchymal brain vessels,
and leptomeningeal vessels. Yet, overexpression of
FIGURE 1 The Continuum of Cardiovascular and Neurotoxic Effects of Ab Peptides
(A) Amyloid-beta (Ab) 1-42 peptides have been found in brain parenchymal and cardiac depositions and, to a lesser extent, in vessels. Depositions composed of Ab1-40
peptides have been described mainly in the heart and vessels including several vascular beds ranging from: (1) leptomeningeal and cortical vessels in cerebral amyloid
angiopathy (CAA); to (2) cerebral microvasculature; (3) intracerebral arteries/circle of Willis; (4) carotid arteries; (5) aorta; and (6) coronary/extracerebral arteries. (B)
Brain Ab deposits trigger a number of events involved in neuronal dysfunction clinically manifested as cognitive decline and progressive Alzheimer’s type dementia.
Cardiac depositions are associated with cardiomyocyte dysfunction. Vascular Ab deposition induces functional changes (vascular stiffening) and promotes vascular
inflammation and atherosclerosis. Aging-associated Ab-induced cardiovascular disease leads to cerebral hypoperfusion, which is a risk factor for vascular, Alzheimer’s,
or mixed dementia.
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955Ab1-42 promotes Ab1-40 vascular depositions in the
brain (22), and factors that alter the Ab1-40/-42 ratio,
such as human apolipoprotein E4 (23), favor amyloid
deposits in the form of CAA compared with paren-
chymal plaques. This differential tissue preference of
Ab species may be explained by the following obser-
vations: 1) using 3D models of cerebrovascular ves-
sels, researchers have recently demonstrated that
HDL and apolipoprotein E (ApoE) synergistically
promote vascular clearance of Ab1-42 more than that
of Ab1-40 (24); 2) Ab1-40 is produced in significant
amounts from platelets, plaque invading macro-
phages (25), endothelial cells (26), and vascular
smooth muscle cells (27); and 3) different ApoE iso-
forms, which are proteins with an impact in choles-
terol transport system, seem to differentially regulate
Ab production, aggregation, and clearance (28). Morespecifically, ApoE4 may inhibit Ab clearance by
competitively binding to the low-density lipoprotein
receptor-related protein 1, and its presence has been
associated with brain Ab accumulation and increased
AD risk. Interestingly, ApoE seems to affect also Ab
kinetics in blood (29).
Ab AND SUBCLINICAL VASCULAR DISEASE. Ab1-40
is critically involved in vascular aging. SIRT1, a class
III histone deacetylase, plays a pivotal protective role
in vascular aging (30) as it up-regulates a-secretase
activity shifting Ab metabolism towards the
non-amyloidogenic pathway (Figure 2). However,
activation of the amyloidogenic pathway results in
impairment of the vasodilating properties of small
arterioles by enhancement of endothelin-1 expression
(31), reduction of eNOS activity and endothelium-
CENTRAL ILLUSTRATION The Alzheimer’s Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease
Stakos, D.A. et al. J Am Coll Cardiol. 2020;75(8):952–67.
Several factors alter APP/Ab metabolism by promoting amyloidogenic pathways leading to increased Ab1-40 blood levels. Subsequent deposition of Ab1-40 in heart
and vessels induces cell damage, accelerating arterial stiffening, atherosclerosis, and cardiac dysfunction, which are manifestations of cardiovascular aging and
disease. Epidemiological evidence supports the clinical relevance of these effects. Ab1-40 blood levels fulfill several criteria as a cardiovascular prognostic biomarker
for risk stratification. Lifestyle and medical interventions interfere with Ab1-40 levels. Ab ¼ amyloid-beta; APP ¼ amyloid precursor protein; CVD ¼ cardiovascular
disease; SNP ¼ single-nucleotide polymorphism.
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FIGURE 2 APP and Ab Metabolism
Following (1) amyloid precursor protein (APP) gene transcription, (2) APP is cleaved in the nonamyloidogenic pathway (plasma membrane) by a- and g- secretases or in
the amyloidogenic pathway (endosomes) by b- and g- secretases. The later pathway generates amyloid beta (Ab) peptides that are released extracellularly. (3) Ab
accumulation in blood or tissues may result from enhanced production/cleavage or by (4) impaired degradation and/or (5) clearance. ACE ¼ angiotensin converting
enzyme; AICD ¼ amyloid precursor protein intracellular domain; apoE ¼ apolipoprotein E; HDL ¼ high-density lipoprotein; IDE ¼ insulin degrading enzyme;
sAPP ¼ soluble amyloid precursor protein.
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957dependent vasodilation, enhancement of oxidative
stress (32), and increased responsiveness to vaso-
constrictors (33) (Table 1, Figure 3). Further, Ab olig-
omers may inhibit telomerase activity leading to
telomere shortening (34), which actively promotes
vascular aging. This experimental evidence generates
the hypothesis that increased Ab systemic concen-
trations may be associated with measurable, acceler-
ated arterial aging and deteriorated vascular function
and structure in humans. Arterial pulse wave velocity
is a well-established, noninvasive marker of arterial
stiffness and vascular aging (35). Interestingly, the
severity of cerebral b-amyloid deposition measured
by positron emission tomography scan and its change
over 2-year follow-up was associated with higher
pulse wave velocity in nondemented elderly adults
(36,37). To assess whether Ab1-40 is involved in early
processes of arterial disease and aging, weprospectively examined changes in pulse wave ve-
locity and plasma Ab1-40 in 107 young to middle-aged
healthy adults (mean age 46.2 years), clinically fol-
lowed for 5 years (38). We found that the 5-year
change of plasma Ab1-40 levels was an independent
determinant of the 5-year change in aortic stiffness.
Because Ab1-40 deposits have been found in carotid
human atherosclerotic plaques (25,39) and aortas (21),
we examined whether plasma Ab1-40 levels are
associated with subclinical atherosclerosis in a pop-
ulation of 394 individuals with a wide range of CVD
risk profiles. After adjustment for age, traditional
CVD risk factors, and renal function, increased
Ab1-40 was independently associated with higher
carotid intima-media thickness, lower ankle-brachial
index, and the severity and extent of arterial dam-
age assessed in the carotid and femoral arteries,
aorta, and coronary circulation (38). Plasma Ab1-40
TABLE 1 Role of APP and Ab in Cardiovascular Biology and Disease
Molecule Study Design Tissue or Cell-Specific Effects Ref. #
Endothelial Cells
APP Murine and human cell line Increased protein levels of proinflammatory mediators (COX-2, VCAM-1) and increased secretion of
IL-1b and Ab1-40 through Src kinase signaling pathway
(69)
Ab1–40 Human cell line Increased expression of inflammatory genes (MCP-1, GRO, IL-1b, and IL-6) through JNK-AP1
signaling pathway
(48,70)
Ab1–40 Rat cell line Increase of endoplasmic reticulum stress through unfolded protein response (71)
Ab1–40 Human, mouse, rat, and bovine
cell line
Inhibition of the KCa2þ channel opening and reduced Ca2þ efflux (71,72)
Ab1–40 Human and rat cell line Activation of caspase-dependent and -independent apoptosis through caspase 12 and cytochrome c (48,71)
Ab1–40
Ab1–42
Ab25–35
Human, mouse, bovine, and porcine
cell line, rat arteries
Inhibition of NO signaling in a concentration-manner through interaction with CD36 (72,73)
Ab1–40
Ab1–42
Human cell line Signature transcriptomic of essential endothelial function affected (48)
Smooth Muscle Cells
Ab1–42 Human and porcine cell line Decrease in sGC activity and cGMP production (73)
Cardiomyocytes
Ab1–40
Ab1–42
Murine and human cell line Decrease of cell viability (48)
Monocytes
APP Murine and human cell line Recruitment of tyrosine kinases Lyn and Syk to APP during b1 integrin-mediated adhesion of
monocyte through tyrosine kinase mechanism
(69,74,75)
Ab1–42 Human monocytes Differentiation of monocytes into macrophages (76)
Ab1–40
Ab1–42
Ab25–35
Human monocytes
Human cell line
Hypersecretion of inflammatory cytokines (TNF-a and IL-1b) and chemokines (MCP-1, IL-8,
MIP-1 a, and CCR5) through activation of ERK-1/-2
(43,76-79)
Ab1–40
Ab1–42
Ab25–35
Human and murine cell line Secretion of ROS (79)
Ab1-40 Human cell line Migration of monocyte through ERK-1/-2 and RAGE receptor (74,80)
Ab1-40
Ab1-42
Human cell Opsonization of lipoproteins enhances their uptake by human monocytes, resulting in
cholesterol accumulation
(81)
Macrophages
Ab1–40 Murine cell line Enhanced nitrite production in the presence of IFN-g macrophage activation (25)
Ab1-40
Ab1-42
Human cell Opsonization of lipoproteins enhances their uptake by macrophages, resulting in cholesterol
accumulation
Accelerated formation of foam cells
(81)
Ab1–42 Macrophages from CD36/ mice Production of ROS and proinflammatory cytokines IL-1b and TNF-a through CD36 signaling (82,83)
Platelets
sAPP695a
sAPP751a
sAPP770a
Human platelet Inhibition of platelet aggregation and secretion (84)
Ab1–40 Amyloid properties induced in
unrelated proteins to stimulate
human and murine platelets
Platelet aggregation through either a CD36-p38MAPK-TXA2 or a glycoprotein Iba pathway (85)
Ab1–40
Ab25–35
Human platelet Platelet aggregation with Ca2þ mobilization and PLC g 2-PKC pathway activation (86)
Ab25–35 Human and murine platelet Platelet activation through RhoA-dependent modulation of actomyosin
Increase in intracellular Ca2þ, leading to dense granule release and ADP secretion
(87,88)
Ab1–40
Ab1–42
Ab25–35
Human and murine platelet Platelet adhesion and spreading through the elongation of filopodia and lamellipodia (89,90)
Ab1-42 Human plasma Thrombin generation in an FXII-dependent FXI activation (91)
Ab1–40 Human and murine platelet ROS generation and cell shrinkage (89)
APP Overexpression of human APP
isoform 770 in mice platelets
Marked inhibition of thrombosis in vivo (85)
APP Overexpression of human APP
isoform 751 in mice
Prothrombotic phenotype in vivo (61)
APP ¼ amyloid precursor protein; Ab ¼ amyloid beta; CCR5 ¼ chemokine receptor type 5; cGMP ¼ cyclic guanosine monophosphate; COX ¼ cyclooxygenase; ERK ¼ extracellular signal–regulated kinase;
FX ¼ coagulation factor.; GRO ¼ growth-related oncogene; IL ¼ interleukin; IFN ¼ interferon; JNK-AP ¼ c-Jun N-terminal kinase–activator protein; MCP ¼ monocyte chemo-attractant protein;
MIP ¼macrophage inflammatory protein; NO ¼ nitric oxide; PKC ¼ protein kinase C; PLC¼ phospholipase C; RAGE¼ receptor advanced glycation end products; ROS ¼ reactive oxygen species; sGC¼ soluble
guanylyl cyclase; TNF ¼ tumor necrosis factor; TXA2 ¼ thromboxane A2; VCAM ¼ vascular cell adhesion molecule.
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FIGURE 3 Detrimental Cellular and Molecular Effects of Ab1-40 in the Cardiovascular System
Excess in blood Ab1-40 levels exerts detrimental effects in vascular and blood cells promoting endothelial activation, atherosclerosis, and atherothrombosis.
IL ¼ interleukin; iNOS ¼ inducible isoform of nitric oxide synthases; LDL ¼ low-density lipoprotein; MCP ¼ monocyte chemoattractant protein; NO ¼ nitric oxide;
ROS ¼ reactive oxygen species; TNF ¼ tumor necrosis factor; VCAM ¼ vascular cell adhesion molecule; VSMC ¼ vascular smooth muscle cells.
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959was also associated with the severity of coronary
artery calcium score in a sample of 3,266 adults
from the Dallas Heart Study without clinically overt
CVD (40).
Overall, these findings are indicative of direct and
indirect roles of Ab1-40 in accelerated arterial aging,
atherosclerosis at various stages, and vascular beds,
taking place long before the establishment of clini-
cally overt CVD.
Ab1-40 IN CORONARY ARTERY DISEASE. Circulating
Ab1-40 levels were independently associated with the
presence of angiographically documented stablecoronary artery disease (CAD) in 2 independent co-
horts consisting of 514 and 396 patients (38). This
association was confirmed in subsequent studies,
including adults with normal cognitive function or
patients with AD (41,42).
Experimental evidence indicates that Ab peptides
may be actively involved in downstream pathways
leading to plaque rupture, thrombosis, and subse-
quent clinical manifestations of the acute coronary
syndrome (ACS) (Figure 3). Ab1-40 stimulates platelet
activation and adhesion in humans and mice (Table 1)
and induces release of matrix metalloproteinases by
TABLE 2 Off-Target Effects of Statins on Ab Metabolism and Accumulation
Intervention/Condition Cell Type/Population Effects on Ab Metabolism Ref. #
Lovastatin (escalating doses
10–60 mg OD)
Double-blind, randomized, placebo-controlled clinical
study of 94 patients with hypercholesterolemia,
12 weeks
Serum levels of total Ab are reduced in a dose-dependent
manner
(92)
Simvastatin (20 mg OD) Prospective interventional clinical trial of 19 patients
with AD, 12 weeks
CSF levels of alpha and beta-secretase-cleaved APP
decreased, no change in plasma levels of Ab1-42
(93)
Pravastatin (10 mg OD) Prospective observational clinical study of 46 patients
with hyperlipidemia, 6 months
No change in plasma levels of Ab1-40 and Ab1-42 (94)
Simvastatin (20–80 mg OD) or
Atorvastatin (20–80 mg OD)
Prospective interventional randomized clinical trial of 39
patients with hypercholesterolemia, 9 months
No change in plasma levels of Ab1-40, Ab1-42, or total Ab (95)
Simvastatin (escalating 40–80 mg OD) Prospective open-label trial of 12 patients with AD or
mild cognitive impairment and
hypercholesterolemia, 12 weeks
No change in plasma levels of Ab1-40 (96)
Simvastatin
Lovastatin
Neuronal cell culture,
Guinea pigs
Decreased production of Ab1-40 and Ab1-42 in neurons
in vitro
Decreased CSF levels of Ab1-40 (47%) and Ab1-42 (62%)
(97)
Lovastatin
Simvastatin
HEK cells Inhibited dimerization of b-secretase
Decreased intracellular production of total Ab
(98)
Fluvastatin C57BL/6 mice neurons
HBME cells
Increased APP-CTF clearance to the lysosome in neurons
Increased LRP-1 and Ab uptake in HBME
(99)
Simvastatin PBCE cells
3x Tg AD mice
Increased LRP1 and apoJ expression
Reduced Ab uptake by PBCEC
Decreased production of APP-CTFs in brain capillary
endothelial cells of mice neurons
(100)
Ab ¼ amyloid beta; AD ¼ Alzheimer’s disease; apoJ ¼ apolipoprotein J; APP ¼ amyloid precursor protein; APP-CTF ¼ amyloid precursor protein C-terminal fragment; CSF ¼ cerebrospinal fluid;
HBME ¼ human brain micro-endothelial cells; HEK cells ¼ human embryonic kidney cells; LRP ¼ low density lipoprotein receptor-related protein; OD ¼ oral dose; PBCE ¼ porcine brain capillary endothelial
cells; 3x Tg AD mice ¼ transgenic Alzheimer’s disease mice.
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(43). Interestingly, in a myocardial infarction rat
model, early surges in plasma sAPP770 concentrations
preceded the release of cardiac injury enzymes (26),
while plasma sAPP was also increased in patients with
ACS (26), suggesting that enhanced APP/Ab processing
and subsequent release of sAPP770 and Ab1-40 may
trigger plaque rupture or its sequalae in ACS. In sup-
port of this hypothesis (Figure 3), we recently reported
that in 2 independent cohorts of patients with non-ST-
segment elevation ACS, higher blood Ab1-40 levels
were associated with worse risk profile, including a
higher GRACE (Global Registry of Acute Coronary
Events) score high sensitivity cardiac troponin T and
lower systolic blood pressure and estimated glomer-
ular filtration rate (44), implying a concentration-
dependent relation of Ab with the severity of ACS.
Overall, the results of these studies provide concep-
tual proof that Abmetabolism is enhanced in CAD and
Ab1-40 levels in blood are increased and associated
with its clinical presentation.
Ab1-40, MORTALITY, AND
RISK STRATIFICATION
GENERAL POPULATION. High plasma Ab1-40 con-
centrations were independently associated with
increased risk of mortality in 1,254 elderly subjects
after adjustment for CVD risk factors and frailty (45).However, significance was lost after adjustment for
cystatin C, suggesting that this association may be
mediated by differences in renal function and/or in-
flammatory status. The prognostic value of circu-
lating Ab1-40 in nonelderly subjects from the general
population as well as its reclassification potential
remain unknown.
CORONARY ARTERY DISEASE. We have recently
shown that circulating Ab1-40 blood levels measured
in 2 independent populations of patients with stable
CAD were predictive of a 3-fold increased risk of
cardiovascular death for highest versus lowest quar-
tile (38). Importantly, adding Ab1-40 improved risk
stratification over the best predictive model by
reclassifying 22% of the population to correct risk
categories for cardiovascular mortality.
In-hospital and midterm mortality in patients with
ACS vary considerably from <1% to >8% according to
risk score calculators (46,47). However, no indexes of
vascular inflammation are currently included in risk
estimation scores such as the widely recommended
GRACE score assessing mortality (46,47). To this end,
we have demonstrated that measuring Ab1-40 in pa-
tients with non–ST-segment elevation ACS improves
prognostic assessment and provides incremental
reclassification value over the GRACE score (44). A
single measurement of circulating Ab1-40 at presen-
tation was independently associated with mortality
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tially improved risk stratification of patients with
non–ST-segment elevation ACS into correct risk cat-
egories over the GRACE score (net reclassification
index 33.4% to 47.1%).
Collectively, these findings suggest that Ab1-40
may be a clinically useful risk biomarker in stable CAD
and particularly in non–ST-segment elevation ACS
where Ab1-40’s performance was complementary to
that of the GRACE score, a commonly used risk score
in clinical practice. However, clinical application of
this peptide as a biomarker needs further research to
set reference values and thus allow its investigation
as part of novel prognostic algorithms in CAD.
Ab1-40 AND CARDIAC FUNCTION. A deregulation of
the BACE1/Ab1-40 axis was identified in the hearts of
nondemented individuals with ischemic heart failure
(48), whereas histology confirmed Ab1-40 and -42
aggregates in the heart of patients with AD (49),
suggesting a novel form of aging-related cardiac
amyloidosis that merits further investigation. Mech-
anistically, both peptides exert toxic effects on car-
diomyocytes resulting in poorer cell viability and
apoptosis (48,49). Treatment of zebrafish embryos
with Ab1-40 peptides induces impaired vascular
development and angiogenesis (50), possibly by
interfering with VEGF pathway (51). Because ischemia
promotes both APP up-regulation and cleavage (52),
and Ab1-40 may induce vasoconstriction and reduced
endothelium-dependent vasodilatation (53), the
pathogenic consequences of short- or long-term
myocardial ischemia on heart failure via enhanced
cardiac amyloidogenesis should be explored.
Many aspects of Ab-related cardiac amyloidosis
are supported by clinical findings. Plasma Ab1-40 has
been associated with markers of cardiac dysfunction
in several clinical conditions with variable degrees of
myocardial functional impairment. We have recently
demonstrated that in 3,266 individuals without
clinically overt CVD from the Dallas Heart Study who
underwent cardiac magnetic resonance imaging,
plasma Ab1-40 was associated with increased circu-
lating N-terminal pro–B-type natriuretic peptide and
high sensitivity cardiac troponin T, indicative of
involvement of this peptide in early subclinical
myocardial stretch and injury (40). Interestingly, we
also found an association of Ab1-40 with lower left
atrial emptying fraction after adjustment for CVD
risk factors. In contrast, although stroke volume
index was lower at higher levels of Ab1-40 by uni-
variate analysis, we observed no independent asso-
ciations with more advanced cardiac abnormalities
such as left ventricular systolic dysfunction orremodeling, possibly because the population under
study was free of established heart disease and such
late changes were not discernible. Indeed, increased
plasma Ab1-40 was found in patients with estab-
lished CAD and lower left ventricular ejection frac-
tion (38). Given that Ab1-40 is associated with lower
cardiorespiratory fitness (VO2 max) independently of
daily activity (40) and with left atrial dysfunction,
further studies are needed to assess whether lower
VO2 max is of cardiac origin possibly related to Ab1-
40–mediated subclinical myocardial damage.
Accordingly, the presence of Ab1-40 in the heart has
been associated with echocardiographic findings of
early diastolic dysfunction (49). Furthermore, in a
prospective study of 939 patients with heart failure
showing reduced or preserved ejection fraction,
plasma Ab1-40 levels were associated with symp-
toms of heart failure as described in New York Heart
Association’s functional classification system (54).
Because diastolic dysfunction and heart failure with
preserved ejection fraction are considered promi-
nent manifestations of myocardial aging (55), blood
concentrations of Ab1-40 may reflect the extent of its
vascular and myocardial involvement in CVD. The
clinical relevance of this concept is supported by
recent findings showing that circulating Ab1-40
predicts adverse clinical outcomes and mortality
and improves risk stratification in patients with
heart failure (54).
EXPERIMENTAL EVIDENCE OF THE LINK BETWEEN
Ab AND CVD. A dementia-CVD continuum hypothe-
sis is further demonstrated through the vascular
involvement of dementia-prone transgenic APP mice.
The Tg2576 mouse model expresses 5 times the
levels of endogenous murine APP (56) and shows
progressive impairment of cognitive function
together with Ab1-40–dependent (57) and ROS-
mediated (53,58) endothelial dysfunction, impaired
vascular reactivity, and 30% attenuation in cerebral
blood flow (59). B6Tg2576 mice develop more
extensive aortic lesions than control mice when fed
the same atherogenic or normal diet under similar
lipid profiles (60). APP23 mice, which overexpress
APP and Ab1-40, show enhanced platelet integrin
activation and degranulation as well as accelerated
thrombus formation (61). Dementia-prone APP23
mice crossed with atherosclerosis-prone apolipopro-
tein E–deficient (ApoE/) mice develop larger and
more inflammatory aortic atherosclerotic lesions
compared with ApoE/ mice (62). Conversely,
ApoE/ mice crossed with animals lacking APP
(APP/) have significantly reduced atherosclerotic
plaque size in thoracic and abdominal aorta (90%
TABLE 3 Off-Target Effects of Antihypertensives and Heart Failure Treatment on Ab Metabolism and Accumulation
Intervention/Condition Cell Type/Population Effects on Ab Metabolism Ref. #
ACE Inhibitors
Captopril CHO cells,
HEK293 cells
ACE degrades Ab1-40 and -42
ACE inhibition increases total Ab levels
(65)
Captopril Tg2576 mice,
Post-mortem human brain tissue
ACE converts Ab1-42 to Ab1-40
ACE inhibition increases Ab1-42 deposition in human and mice neurons
(101)
Trandolapril Tg2576 mice Decreased brain Ab1-40 and Ab1-42
Increased plasma Ab1-40 and Ab1-42 (x2.5)
(102)
Lisinopril (2.5–80 mg daily)
Enalapril (10 mg daily)
Benazepril (10 mg daily)
Observational clinical study of
22 patients with mild cognitive
impairment
Increased Ab1-42 levels and Ab1-42/-40 ratio in plasma (103)
ARBs
Losartan SHRSP rats Decreased content of Ab1-40 (30%) and Ab1-42 (25%) by enhancing
insulin-degrading enzyme, neprilysin, and transthyretin expression in
brain
(104)
Olmesartan APP23 transgenic mice Olmesartan prevents Ab1-40 induced elevation of ROS
Ab burden not reduced in brain microvessels
(105)
Candesartan Primary neuron cultures from
Tg2576 mouse embryos
Prevents Ab1-40 and -42 aggregation and Ab1-42 oligomerization in
neurons
(106)
Losartan Tg2576 mice Reduced plasma and brain Ab1-42 (20%), while no changes in Ab1-40
levels
(102)
Candesartan, irbesartan, olmesartan,
valsartan, losartan, telmisartan
eprosartan
Healthy elderly
Cross-sectional study (n ¼ 871)
Prospective study (n ¼ 124)
Increased clearance of Ab1-42 from the brain into CSF (107)
ARNIs
Sacubitril/valsartan (400 mg OD) Double-blind, randomized, placebo-
controlled clinical study of 43
healthy subjects
Treatment increased CSF Ab1-38 peptide and plasma Ab1-40 levels (þ50%) (108)
B-Blockers
ICI 118,551 (beta-blocker used in
experimental conditions)
C57 mice b2 adrenergic receptor blockade attenuates acute stress-induced Ab1-40
(20%) and Ab1-42 (5%) in neurons
(109)
Propranolol SAMP8 mice Propranolol attenuates increases in Ab1-42 and BACE1 and decreases in
IDE expression by shifting APP cleavage to nonamyloidogenic
pathway in neurons
(110)
Propranolol
Carvedilol
Tg2576 mice Propranolol reduces plasma and brain Ab1-40 (40%) and Ab1-42
(50%)
Carvedilol reduces brain Ab1-40 and -42 levels
(102)
Carvedilol N2a cells Protective against endogenous Ab-induced neurotoxicity in neuronal
N2a cells
(111)
CCBs
Nilvadipine, nitrendipine, amlodipine TgPS1/APPsw mice or B6/SJL F1
mice
Nilvadipine and nitrendipine but not amlodipine (acute treatment) reduce
brain content of Ab probably by stimulating clearance through BBB
(112)
Nilvadipine (chronic treatment) reduces amyloid plaque burden in mouse
brain
(112)
Nilvadipine, amlodipine, nifedipine,
nitrendipine
TgPS1/APPsw mice Nilvadipine and nitrendipine increase Ab1-40 and Ab1-42 plasma levels,
while amlodipine and nifedipine had no effect on Ab1-40 or Ab1-42
plasma levels
(112)
Amlodipine, diltiazem, felodipine,
isradipine, nifedipine, nicardipine,
nimodipine, nisoldipine
H4 neuroglioma cells Nifedipine reduces production of Ab1-42 (40%), by increasing a-
secretase and diminishing g-secretase activity
(113)
Nicardipine Tg2576 mice Nicardipine reduces plasma Ab1-40 (30%) and Ab1-42 (50%) (102)
Nitrendipine Primary neuron cultures generated
from Tg2576 mouse embryos
Nitrendipine prevents Ab1-40 and -42 aggregation and Ab1-42
oligomerization in vitro
(106)
Continued on the next page
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ApoE/ mice despite comparable cholesterol levels
(63). More importantly, atherosclerotic plaques in
APP//ApoE/ mice have reduced macrophage
content, increased amount of collagen, and a thicker
fibrous cap indicating a more stable plaquemorphology. Mechanistically, a series of experi-
mental studies summarized in Table 1 present Ab as a
potent proinflammatory, proapoptotic, and proa-
therogenic molecule affecting the function of endo-
thelial cells, platelets, vascular smooth muscle cells,
and macrophages (Figure 3).
TABLE 3 Continued
Intervention/Condition Cell Type/Population Effects on Ab Metabolism Ref. #
Diuretic Agents
Furosemide Tg2576 mice Ab1-40 and -42 brain content decreased
Plasma Ab1-40 and -42 increased (2)
(102)
Furosemide Neurons of Tg2576 mice Furosemide prevents Ab oligomerization in vitro and reduces amyloid
burden (30%) by dissociating pre-aggregated Ab1-42 oligomers
(106)
Hemodialysis
Hemodialysis Cross-sectional study of 30 CKD
patients under hemodialysis
Hemodialysis removes blood Ab1-40 and -42 while plasma Ab remains
decreased longitudinally
(114)
Hemodialysis Prospective study of 26 CKD
patients under hemodialysis
Plasma levels Ab1-40 (35%) and Ab1-42 (22%) reduced after 1
hemodialysis session
(115)
Hemodialysis Prospective clinical study of 30
CKD hemodialysis patients
Long-term hemodialysis leads to reduced or unchanged plasma Ab1-40
while plasma Ab1-42 remains unchanged or increases
(116)
Hemodialysis Cross-sectional study of
47 patients with CKD
Plasma levels of Ab1-40 and -42 are reduced (117)
Peritoneal dialysis Cross-sectional study of
30 patients with CKD
Peritoneal dialysis decreases plasma levels Ab1-40 and -42 (118)
Ab ¼ amyloid beta; ACE ¼ angiotensin-converting enzyme; ARBs ¼ angiotensin receptor blockers; ARNIs ¼ angiotensin receptor/neprilysin inhibitors; BBB ¼ blood brain barrier; CCBs ¼ calcium-channel
blockers; CHO cells ¼ Chinese hamster ovary cells; CKD ¼ chronic kidney disease; CSF ¼ cerebrospinal fluid; HEK cells ¼ human embryonic kidney cells; IDE ¼ insulin degrading enzyme; ROS ¼ reactive
oxygen species; SAMP8 ¼ senescence-accelerated mouse model; SHRSP rats ¼ stroke-prone spontaneously hypertensive rats.
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Ab METABOLISM
LIFESTYLE MODIFICATIONS. A healthy lifestyle,
including adherence to Mediterranean diet, omega-3
fatty acids, and caloric restriction may reduce Ab
brain deposits and exert antiamyloidogenic proper-
ties (Online Table 4). We recently demonstrated that
increased daily activity assessed by accelerometer
recordings and lower physical fitness, as assessed by
VO2 max, in 3,266 participants without CVD from the
Dallas Heart Study were independently associated
with plasma levels of Ab1-40 (40). However, changes
of Ab peptide blood levels over time in response to
physical activity have not been assessed. Yet, accu-
mulating evidence suggests that an unhealthy life-
style such as a high-fat diet and cigarette smoking
(64) may enhance the amyloidogenic pathway (Online
Table 4). These findings suggest that cardiovascular
effects of lifestyle modifications may be partly
mediated by altering Ab metabolism, but further
research should explore these effects in humans,
particularly with regards to Ab1-40 as a direct effector
molecule in cardiovascular disease.
CARDIOVASCULAR MEDICAL TREATMENT. Stat ins .
Experimental evidence indicates that statins reduce
brain and intracellular Ab levels in vitro and in vivo,
by down-regulating its upstream pathway, reducing
cellular uptake of Ab peptides, and enhancing its
clearance through the blood brain barrier (Table 2).
However, results of 2 randomized clinical studiesevaluating blood Ab1-40 peptides after statin
treatment were inconsistent, possibly due to statins’
effect on equilibrium between brain and circulating
Ab (Table 2).
Antihypertensive and heart failure drug treatment.Most
classes of antihypertensive drugs used in clinical
practice influence APP/Ab metabolism (Table 3). In-
hibition of the angiotensin-converting enzyme in-
creases Ab1-40 or Ab1-42 availability due to
attenuation of its breakdown (65) or through blockade
of Ab1-42 conversion to Ab1-40 (65), respectively.
Consequently, plasma levels of Ab1-42 were found to
increase after angiotensin-converting enzyme inhi-
bition, but results of Ab1-40 levels were not consis-
tent, showing either increase or no change (Table 3).
The favorable effects of angiotensin receptor antag-
onists on Ab metabolism shown in the central ner-
vous system (Table 3) have not been investigated on
the cardiovascular system in humans, similar to the
effect of b-blockers, calcium-channel blockers, and
diuretic agents (Table 3).
A new heart failure drug class, the angiotensin
receptor-neprilysin inhibitors, involves the inhibition
of neprilysin, which is an Ab degrading enzyme and
thus may increase Ab1-40 plasma levels (Table 3). In
light of new evidence showing that Ab1-40 blood
levels are associated with increased mortality in pa-
tients with heart failure not receiving angiotensin
receptor-neprilysin inhibitors (54) and that Ab1-40 is
widely expressed in the myocardium of patients with
heart failure (48), it remains unknown whether some
beneficiary effects of angiotensin receptor-neprilysin
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temic Ab1-40 availability. This may be particularly
important in regard to long-term outcomes, as depo-
sition diseases need time to evolve. Peritoneal dial-
ysis and hemodialysis reduce plasma levels of Ab1-40
and -42 (Table 3), supporting the significance of Ab
renal clearance indicating a definite interventional
target on Ab1-40 availability.
Ant i thrombot ic agents . Although some evidence
indicates that at low concentrations, anticoagulant
agents may increase Ab metabolism, most experi-
mental studies indicate that mainly due to their
glycosaminoglycan structure, heparin and enox-
aparin inhibit Ab neurotoxic effects by affecting APP
function and BACE1 activity (Online Table 5). How-
ever, whether these protective effects are extended
systemically to the cardiovascular system merits
further investigation. In contrast, 1 experimental
study showed that treatment of C57BL/6 mice with
anticoagulants greatly increased plasma levels of Ab
(>20-fold) (66) through down-regulation of the factor
XII–factor VII pathway, which is involved in Ab
degradation (66). Clopidogrel or aspirin may interfere
with APP/Ab generation from platelets, but further
studies are needed to confirm this relationship
(Online Table 5).
Finally, although most phase III trials assessing
antiamyloid-specific, targeted therapies were nega-
tive regarding efficacy in AD (67), their impact on CVD
is unknown and merits further investigation.
CONCLUSIONS AND FUTURE DIRECTIONS
Several issues merit clarification. Although patients
with CAD are more likely to develop AD-like
neuropathological lesions than those without CAD
(68), whether atherogenesis occurs in parallel or
independently from brain parenchyma amyloid load
in humans is unknown. In B6Tg2576 mice, brain Ab
load is positively correlated with the area of aortic
atherosclerotic lesions, while APP23/ApoE/ mice
developed aortic atherosclerotic lesions well before
any parenchymal brain depositions (62). The asso-
ciation between Ab1-40 and normal or premature
cardiovascular aging needs to be further elucidated.
Understanding the mechanisms responsible for the
vascular preference of Ab1-40 over -42 can
elucidate the precise biological role of this peptide
in the complex pathophysiology of vascular
inflammation.A pathophysiological role of Ab1-40 across the
continuum of cardiovascular disease is suggested
through its independent association with a broad
spectrum of vascular and cardiac involvement from
early functional vascular alterations and subclinical
atherosclerosis to overt symptomatic CAD, ACS, and
heart failure. This is robustly supported by experi-
mental evidence that APP and Ab1-40 are critically
involved in vascular inflammation, vascular and car-
diac aging, and atherothrombosis. The association of
Ab1-40 with mortality has been consistently shown in
a total population of about 5,000 patients in 6 inde-
pendent cohorts derived from 8 countries. Thus,
Ab1-40 fulfills several criteria for consideration as a
new biomarker for risk stratification in cardiovascular
disease, including proof of concept, clinical utility,
prospective validation, incremental and reclassifica-
tion value for risk prediction, and ease of use. The
implementation of a universally accepted method of
sampling, preparation, storage, and measurement of
circulating Ab1-40 in plasma and the definition of
normal and reference values as well as the conduc-
tion of studies with strict protocols of measurement
in well-defined populations will allow the clinical
application of this peptide as a new risk biomarker in
patients with established cardiovascular disease.
Interestingly, the association of Ab1-40 with sub-
clinical functional vascular alterations in healthy in-
dividuals and its association with all-cause mortality
in the general population indicate that it should be
further tested as a possible biomarker of cardiovas-
cular risk in primary prevention as well. Most
importantly, multiple lines of evidence clearly indi-
cate that manipulating APP/Ab turnover and aggre-
gation or blocking its inflammatory reactions is
feasible, potentially improving our understanding
and means to simultaneously protect the brain, heart,
and vessels during physiological or premature aging.
ACKNOWLEDGMENT The authors express their grat-
itude to Dr. Kerida Shook for proofreading the
manuscript.
ADDRESS FOR CORRESPONDENCE: Dr. Konstantinos
Stellos, Cardiovascular Disease Prevention Hub,
Biosciences Institute, Faculty of Medical Sciences,
Newcastle University, International Centre for Life,
Central Parkway, Newcastle Upon Tyne NE1 3BZ,
United Kingdom. E-mail: konstantinos.stellos@ncl.
ac.uk. Twitter: @K_Stellos, @UniofNewcastle.
J A C C V O L . 7 5 , N O . 8 , 2 0 2 0 Stakos et al.
M A R C H 3 , 2 0 2 0 : 9 5 2 – 6 7 Ab in CVD
965RE F E RENCE S1. Gottesman RF, Albert MS, Alonso A, et al. As-
sociations between midlife vascular risk factors
and 25-year incident dementia in the Atheroscle-
rosis Risk in Communities (ARIC) cohort. JAMA
Neurol 2017;74:1246–54.
2. Deschaintre Y, Richard F, Leys D, Pasquier F.
Treatment of vascular risk factors is associated
with slower decline in Alzheimer disease.
Neurology 2009;73:674–80.
3. Roher AE, Tyas SL, Maarouf CL, et al. Intracra-
nial atherosclerosis as a contributing factor to
Alzheimer’s disease dementia. Alzheimers Dement
2011;7:436–44.
4. Breteler MM, Claus JJ, Grobbee DE, Hofman A.
Cardiovascular disease and distribution of cogni-
tive function in elderly people: the Rotterdam
Study. BMJ 1994;308:1604–8.
5. Hardy JA, Higgins GA. Alzheimer’s disease: the
amyloid cascade hypothesis. Science 1992;256:
184–5.
6. Pantoni L. Cerebral small vessel disease: from
pathogenesis and clinical characteristics to thera-
peutic challenges. Lancet Neurol 2010;9:689–701.
7. Koyama A, Okereke OI, Yang T, Blacker D,
Selkoe DJ, Grodstein F. Plasma amyloid-b as a
predictor of dementia and cognitive decline: a
systematic review and meta-analysis. Arch Neurol
2012;69:824–31.
8. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-
secretase cleavage of Alzheimer’s amyloid pre-
cursor protein by the transmembrane aspartic
protease BACE. Science 1999;286:735–41.
9. Tanzi RE, Bertram L. Twenty years of the Alz-
heimer’s disease amyloid hypothesis: a genetic
perspective. Cell 2005;120:545–55.
10. Kang J, Lemaire HG, Unterbeck A, et al. The
precursor of Alzheimer’s disease amyloid A4 pro-
tein resembles a cell-surface receptor. Nature
1987;325:733–6.
11. Kumar DK, Choi SH, Washicosky KJ, et al. Am-
yloid-b peptide protects against microbial infec-
tion in mouse and worm models of Alzheimer’s
disease. Sci Transl Med 2016;8. 340ra72.
12. Van Nostrand WE, Schmaier AH, Farrow JS,
Cunningham DD. Platelet protease nexin-2/
amyloid beta-protein precursor. Possible patho-
logic and physiologic functions. Ann N Y Acad Sci
1991;640:140–4.
13. Obregon D, Hou H, Deng J, et al. Soluble am-
yloid precursor protein-alpha modulates beta-
secretase activity and amyloid-beta generation.
Nat Commun 2012;3:777.
14. van der Kant R, Goldstein LS. Cellular func-
tions of the amyloid precursor protein from
development to dementia. Dev Cell 2015;32:
502–15.
15. Mawuenyega KG, Sigurdson W, Ovod V, et al.
Decreased clearance of CNS beta-amyloid in Alz-
heimer’s disease. Science 2010;330:1774.
16. Casoli T, Di Stefano G, Giorgetti B, et al.
Release of beta-amyloid from high-density plate-
lets: implications for Alzheimer’s disease pathol-
ogy. Ann N Y Acad Sci 2007;1096:170–8.17. Burgermeister P, Calhoun ME, Winkler DT,
Jucker M. Mechanisms of cerebrovascular amyloid
deposition: lessons from mouse models. Annals of
the New York Academy of Sciences 2000;903:
307–16.
18. Biffi A, Greenberg SM. Cerebral amyloid angi-
opathy: a systematic review. J Clin Neurol 2011;7:
1–9.
19. Wisniewski H, Wegiel J, Vorbrodt A, Mazur-
Kolecka B, Frackowiak J. Part I. Alzheimer’s dis-
ease: vascular concepts, cellular issues, and ge-
netics (plenary lectures)-role of perivascular cells
and myocytes in vascular amyloidosis. Ann N Y
Acad Sci 2000;903:6–18.
20. Roher AE, Esh CL, Kokjohn TA, et al. Amyloid
beta peptides in human plasma and tissues and
their significance for Alzheimer’s disease. Alz-
heimers Dement 2009;5:18–29.
21. Kokjohn TA, Van Vickle GD, Maarouf CL, et al.
Chemical characterization of pro-inflammatory
amyloid-beta peptides in human atherosclerotic
lesions and platelets. Biochim Biophys Acta 2011;
1812:1508–14.
22. McGowan E, Pickford F, Kim J, et al. Ab42 is
essential for parenchymal and vascular amyloid
deposition in mice. Neuron 2005;47:191–9.
23. Fryer JD, Simmons K, Parsadanian M, et al.
Human apolipoprotein E4 alters the amyloid-b 40:
42 ratio and promotes the formation of cerebral
amyloid angiopathy in an amyloid precursor pro-
tein transgenic model. J Neurosci 2005;25:
2803–10.
24. Robert J, Button EB, Yuen B, et al. Clearance
of beta-amyloid is facilitated by apolipoprotein E
and circulating high-density lipoproteins in bio-
engineered human vessels. Eife 2017;6:e29595.
25. De Meyer GR, De Cleen DM, Cooper S, et al.
Platelet phagocytosis and processing of beta-
amyloid precursor protein as a mechanism of
macrophage activation in atherosclerosis. Circ Res
2002;90:1197–204.
26. Kitazume S, Yoshihisa A, Yamaki T, et al. Sol-
uble amyloid precursor protein 770 is released
from inflamed endothelial cells and activated
platelets: a novel biomarker for acute coronary
syndrome. J Biol Chem 2012;287:40817–25.
27. Melchor JP, Van Nostrand WE. Fibrillar amy-
loid beta-protein mediates the pathologic accu-
mulation of its secreted precursor in human
cerebrovascular smooth muscle cells. J Biol Chem
2000;275:9782–91.
28. Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipopro-
tein E and Alzheimer disease: risk, mechanisms
and therapy. Nat Rev Neurol 2013;9:106.
29. Verghese PB, Castellano JM, Garai K, et al.
ApoE influences amyloid-b (Ab) clearance despite
minimal apoE/Ab association in physiological
conditions. Proc Natl Acad Sci U S A 2013;110:
E1807–16.
30. Laina A, Stellos K, Stamatelopoulos K.
Vascular ageing: underlying mechanisms and
clinical implications. Exp Gerontol 2018;109:
16–30.31. Deane R, Du Yan S, Submamaryan RK, et al.
RAGE mediates amyloid-beta peptide transport
across the blood-brain barrier and accumulation in
brain. Nat Med 2003;9:907–13.
32. Park L, Zhou P, Pitstick R, et al. Nox2-derived
radicals contribute to neurovascular and behav-
ioral dysfunction in mice overexpressing the am-
yloid precursor protein. Proc Natl Acad Sci U S A
2008;105:1347–52.
33. Niwa K, Porter VA, Kazama K, Cornfield D,
Carlson GA, Iadecola C. A beta-peptides enhance
vasoconstriction in cerebral circulation. Am J
Physiol Heart Circ Physiol 2001;281:H2417–24.
34. Wang J, Zhao C, Zhao A, Li M, Ren J, Qu X.
New insights in amyloid beta interactions with
human telomerase. J Am Chem Soc 2015;137:
1213–9.
35. Vlachopoulos C, Aznaouridis K, Stefanadis C.
Prediction of cardiovascular events and all-cause
mortality with arterial stiffness: a systematic re-
view and meta-analysis. J Am Coll Cardiol 2010;
55:1318–27.
36. Hughes TM, Kuller LH, Barinas-Mitchell EJ,
et al. Arterial stiffness and beta-amyloid pro-
gression in nondemented elderly adults. JAMA
Neurol 2014;71:562–8.
37. Hughes TM, Kuller LH, Barinas-Mitchell EJ,
et al. Pulse wave velocity is associated with beta-
amyloid deposition in the brains of very elderly
adults. Neurology 2013;81:1711–8.
38. Stamatelopoulos K, Sibbing D, Rallidis LS,
et al. Amyloid-beta (1-40) and the risk of death
from cardiovascular causes in patients with coro-
nary heart disease. J Am Coll Cardiol 2015;65:
904–16.
39. Bucerius J, Barthel H, Tiepolt S, et al. Feasi-
bility of in vivo (18)F-florbetaben PET/MR imaging
of human carotid amyloid-beta. Eur J Nucl Med
Mol Imaging 2017;44:1119–28.
40. Stamatelopoulos K, Pol CJ, Ayers C, et al.
Amyloid-beta (1-40) peptide and subclinical car-
diovascular disease. J Am Coll Cardiol 2018;72:
1060–1.
41. Janelidze S, Stomrud E, Palmqvist S, et al.
Plasma beta-amyloid in Alzheimer’s disease and
vascular disease. Sci Rep 2016;6:26801.
42. Roeben B, Maetzler W, Vanmechelen E, et al.
Association of plasma Abeta40 peptides, but not
Abeta42, with coronary artery disease and dia-
betes mellitus. J Alzheimers Dis 2016;52:161–9.
43. Chong YH, Sung JH, Shin SA, Chung JH,
Suh YH. Effects of the beta-amyloid and carboxyl-
terminal fragment of Alzheimer’s amyloid precur-
sor protein on the production of the tumor ne-
crosis factor-alpha and matrix metalloproteinase-
9 by human monocytic THP-1. J Biol Chem 2001;
276:23511–7.
44. Stamatelopoulos K, Mueller-Hennessen M,
Georgiopoulos G, et al. Amyloid-beta (1-40) and
mortality in patients with non-ST-segment eleva-
tion acute coronary syndrome: a cohort study. Ann
Intern Med 2018;168:855–65.
Stakos et al. J A C C V O L . 7 5 , N O . 8 , 2 0 2 0
Ab in CVD M A R C H 3 , 2 0 2 0 : 9 5 2 – 6 7
96645. Gabelle A, Schraen S, Gutierrez LA, et al.
Plasma beta-amyloid 40 levels are positively
associated with mortality risks in the elderly.
Alzheimers Dement 2015;11:672–80.
46. Roffi M, Patrono C, Collet JP, et al. 2015 ESC
guidelines for the management of acute coronary
syndromes in patients presenting without persis-
tent ST-segment elevation: Task Force for the
Management of Acute Coronary Syndromes in
Patients Presenting without Persistent ST-
Segment Elevation of the European Society of
Cardiology (ESC). Eur Heart J 2016;37:267–315.
47. Amsterdam EA, Wenger NK, Brindis RG, et al.
2014 AHA/ACC guideline for the management of
patients with non-ST-elevation acute coronary
syndromes: a report of the American College of
Cardiology/American Heart Association Task Force
on Practice Guidelines. J Am Coll Cardiol 2014;64:
e139–228.
48. Greco S, Zaccagnini G, Fuschi P, et al.
Increased BACE1-AS long noncoding RNA and
beta-amyloid levels in heart failure. Cardiovasc
Res 2017;113:453–63.
49. Troncone L, Luciani M, Coggins M, et al. Abeta
amyloid pathology affects the hearts of patients
with Alzheimer’s disease: mind the heart. J Am
Coll Cardiol 2016;68:2395–407.
50. Donnini S, Solito R, Cetti E, et al. Abeta pep-
tides accelerate the senescence of endothelial
cells in vitro and in vivo, impairing angiogenesis.
FASEB J 2010;24:2385–95.
51. Hayashi S, Sato N, Yamamoto A, et al. Alz-
heimer disease-associated peptide, amyloid
beta40, inhibits vascular regeneration with in-
duction of endothelial autophagy. Arterioscler
Thromb Vasc Biol 2009;29:1909–15.
52. Saido TC, Yokota M, Maruyama K, et al. Spatial
resolution of the primary beta-amyloidogenic
process induced in postischemic hippocampus.
J Biol Chem 1994;269:15253–7.
53. Thomas T, Thomas G, McLendon C, Sutton T,
Mullan M. beta-Amyloid-mediated vasoactivity
and vascular endothelial damage. Nature 1996;
380:168–71.
54. Bayes-Genis A, Barallat J, de Antonio M, et al.
Bloodstream Amyloid-beta (1-40) Peptide,
Cognition, and Outcomes in Heart Failure. Rev Esp
Cardiol (Engl Ed) 2017;70:924–32.
55. Loffredo FS, Nikolova AP, Pancoast JR, Lee RT.
Heart failure with preserved ejection fraction:
molecular pathways of the aging myocardium. Circ
Res 2014;115:97–107.
56. Hsiao K, Chapman P, Nilsen S, et al. Correlative
memory deficits, Abeta elevation, and amyloid
plaques in transgenic mice. Science 1996;274:
99–102.
57. Davis J, Xu F, Deane R, et al. Early-onset and
robust cerebral microvascular accumulation of
amyloid beta-protein in transgenic mice express-
ing low levels of a vasculotropic Dutch/Iowa
mutant form of amyloid beta-protein precursor.
J Biol Chem 2004;279:20296–306.
58. Giokarini T, Bonafini L, Shearman MS, Hill RG,
Longmore J. Beta-Amyloid (A beta 1-40)-evoked
changes in vascular reactivity are mediated via an
endothelium-specific mechanism: studies usingrabbit isolated aorta. Ann N Y Acad Sci 1997;826:
475–8.
59. Niwa K, Younkin L, Ebeling C, et al. Abeta 1-
40-related reduction in functional hyperemia in
mouse neocortex during somatosensory activa-
tion. Proc Natl Acad Sci U S A 2000;97:9735–40.
60. Li L, Cao D, Garber DW, Kim H, Fukuchi K.
Association of aortic atherosclerosis with cerebral
beta-amyloidosis and learning deficits in a mouse
model of Alzheimer’s disease. Am J Pathol 2003;
163:2155–64.
61. Jarre A, Gowert NS, Donner L, et al. Pre-acti-
vated blood platelets and a pro-thrombotic
phenotype in APP23 mice modeling Alzheimer’s
disease. Cell Signal 2014;26:2040–50.
62. Tibolla G, Norata GD, Meda C, et al. Increased
atherosclerosis and vascular inflammation in APP
transgenic mice with apolipoprotein E deficiency.
Atherosclerosis 2010;210:78–87.
63. Van De Parre TJ, Guns PJ, Fransen P, et al.
Attenuated atherogenesis in apolipoprotein
E-deficient mice lacking amyloid precursor pro-
tein. Atherosclerosis 2011;216:54–8.
64. Moreno-Gonzalez I, Estrada LD, Sanchez-
Mejias E, Soto C. Smoking exacerbates amyloid
pathology in a mouse model of Alzheimer’s dis-
ease. Nat Commun 2013;4:1495.
65. Hemming ML, Selkoe DJ. Amyloid beta-
protein is degraded by cellular angiotensin-
converting enzyme (ACE) and elevated by an
ACE inhibitor. J Biol Chem 2005;280:37644–50.
66. Yang L, Bhattacharya A, Li Y, Zhang Y. Anti-
coagulants inhibit proteolytic clearance of plasma
amyloid beta. Oncotarget 2018;9:5614–26.
67. Makin S. The amyloid hypothesis on trial. Na-
ture 2018;559:S4–7.
68. de la Torre JC. Is Alzheimer’s disease a
neurodegenerative or a vascular disorder? Data,
dogma, and dialectics. Lancet Neurol 2004;3:
184–90.
69. Austin SA, Sens MA, Combs CK. Amyloid pre-
cursor protein mediates a tyrosine kinase-
dependent activation response in endothelial
cells. J Neurosci 2009;29:14451–62.
70. Vukic V, Callaghan D, Walker D, et al.
Expression of inflammatory genes induced by
beta-amyloid peptides in human brain endothelial
cells and in Alzheimer’s brain is mediated by the
JNK-AP1 signaling pathway. Neurobiol Dis 2009;
34:95–106.
71. Fonseca AC, Ferreiro E, Oliveira CR,
Cardoso SM, Pereira CF. Activation of the
endoplasmic reticulum stress response by the
amyloid-beta 1-40 peptide in brain endothelial
cells. Biochim Biophys Acta 2013;1832:2191–203.
72. Price JM, Chi X, Hellermann G, Sutton ET.
Physiological levels of beta-amyloid induce cere-
bral vessel dysfunction and reduce endothelial
nitric oxide production. Neurol Res 2001;23:
506–12.
73. Miller TW, Isenberg JS, Shih HB, Wang Y,
Roberts DD. Amyloid-beta inhibits No-cGMP
signaling in a CD36- and CD47-dependent
manner. PLoS One 2010;5:e15686.74. Sondag CM, Combs CK. Amyloid precursor
protein mediates proinflammatory activation of
monocytic lineage cells. J Biol Chem 2004;279:
14456–63.
75. Sondag CM, Combs CK. Adhesion of mono-
cytes to type I collagen stimulates an APP-
dependent proinflammatory signaling response
and release of Abeta1-40. J Neuroinflammation
2010;7:22.
76. Fiala M, Zhang L, Gan X, et al. Amyloid-beta
induces chemokine secretion and monocyte
migration across a human blood-brain barrier
model. Mol Med 1998;4:480–9.
77. Giri RK, Selvaraj SK, Kalra VK. Amyloid
peptide-induced cytokine and chemokine expres-
sion in THP-1 monocytes is blocked by small
inhibitory RNA duplexes for early growth
response-1 messenger RNA. J Immunol 2003;170:
5281–94.
78. Giri RK, Rajagopal V, Shahi S, Zlokovic BV,
Kalra VK. Mechanism of amyloid peptide induced
CCR5 expression in monocytes and its inhibition by
siRNA for Egr-1. Am J Physiol Cell Physiol 2005;
289:C264–76.
79. Bamberger ME, Harris ME, McDonald DR,
Husemann J, Landreth GE. A cell surface receptor
complex for fibrillar beta-amyloid mediates
microglial activation. J Neurosci 2003;23:2665–74.
80. Giri R, Shen Y, Stins M, et al. beta-amyloid-
induced migration of monocytes across human
brain endothelial cells involves RAGE and PECAM-
1. Am J Physiol Cell Physiol 2000;279:C1772–81.
81. Schulz B, Liebisch G, Grandl M, Werner T,
Barlage S, Schmitz G. Beta-amyloid (Abeta40,
Abeta42) binding to modified LDL accelerates
macrophage foam cell formation. Biochim Biophys
Acta 2007;1771:1335–44.
82. El Khoury JB, Moore KJ, Means TK, et al. CD36
mediates the innate host response to beta-amy-
loid. J Exp Med 2003;197:1657–66.
83. Moore KJ, El Khoury J, Medeiros LA, et al.
A CD36-initiated signaling cascade mediates in-
flammatory effects of beta-amyloid. J Biol Chem
2002;277:47373–9.
84. Henry A, Li QX, Galatis D, et al. Inhibition of
platelet activation by the Alzheimer’s disease
amyloid precursor protein. Br J Haematol 1998;
103:402–15.
85. Herczenik E, Bouma B, Korporaal SJ, et al.
Activation of human platelets by misfolded pro-
teins. Arterioscler Thromb Vasc Biol 2007;27:
1657–65.
86. Shen MY, Hsiao G, Fong TH, Chou DS, Sheu JR.
Expression of amyloid beta peptide in human
platelets: pivotal role of the phospholipase
Cgamma2-protein kinase C pathway in platelet
activation. Pharmacol Res 2008;57:151–8.
87. Sonkar VK, Kulkarni PP, Dash D. Amyloid beta
peptide stimulates platelet activation through
RhoA-dependent modulation of actomyosin or-
ganization. FASEB J 2014;28:1819–29.
88. Canobbio I, Guidetti GF, Oliviero B, et al.
Amyloid beta-peptide-dependent activation of
human platelets: essential role for Ca2þ and ADP
in aggregation and thrombus formation. Biochem
J 2014;462:513–23.
J A C C V O L . 7 5 , N O . 8 , 2 0 2 0 Stakos et al.
M A R C H 3 , 2 0 2 0 : 9 5 2 – 6 7 Ab in CVD
96789. Gowert NS, Donner L, Chatterjee M, et al.
Blood platelets in the progression of Alzheimer’s
disease. PLoS One 2014;9:e90523.
90. Canobbio I, Catricala S, Di Pasqua LG, et al.
Immobilized amyloid Abeta peptides support
platelet adhesion and activation. FEBS Lett 2013;
587:2606–11.
91. Zamolodchikov D, Renne T, Strickland S. The
Alzheimer’s disease peptide beta-amyloid pro-
motes thrombin generation through activation of
coagulation factor XII. J Thromb Haemost 2016;
14:995–1007.
92. Friedhoff LT, Cullen EI, Geoghagen NS,
Buxbaum JD. Treatment with controlled-release
lovastatin decreases serum concentrations of hu-
man beta-amyloid (A beta) peptide. Int J Neuro-
psychopharmacol 2001;4:127–30.
93. Sjogren M, Gustafsson K, Syversen S, et al.
Treatment with simvastatin in patients with Alz-
heimer’s disease lowers both alpha- and beta-
cleaved amyloid precursor protein. Dement Ger-
iatr Cogn Disord 2003;16:25–30.
94. Ishii K, Tokuda T, Matsushima T, et al. Pra-
vastatin at 10 mg/day does not decrease plasma
levels of either amyloid-beta (Abeta) 40 or Abeta
42 in humans. Neurosci Lett 2003;350:161–4.
95. Hoglund K, Wiklund O, Vanderstichele H,
Eikenberg O, Vanmechelen E, Blennow K. Plasma
levels of beta-amyloid(1-40), beta-amyloid(1-42),
and total beta-amyloid remain unaffected in adult
patients with hypercholesterolemia after treat-
ment with statins. Arch Neurol 2004;61:333–7.
96. Serrano-Pozo A, Vega GL, Lutjohann D, et al.
Effects of simvastatin on cholesterol metabolism
and Alzheimer disease biomarkers. Alzheimer Dis
Assoc Disord 2010;24:220–6.
97. Fassbender K, Simons M, Bergmann C, et al.
Simvastatin strongly reduces levels of Alzheimer’s
disease beta -amyloid peptides Abeta 42 and
Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U
S A 2001;98:5856–61.
98. Parsons RB, Price GC, Farrant JK,
Subramaniam D, Adeagbo-Sheikh J, Austen BM.
Statins inhibit the dimerization of beta-secretase
via both isoprenoid- and cholesterol-mediated
mechanisms. Biochem J 2006;399:205–14.
99. Shinohara M, Sato N, Kurinami H, et al.
Reduction of brain beta-amyloid (Abeta) by flu-
vastatin, a hydroxymethylglutaryl-CoA reductase
inhibitor, through increase in degradation of am-
yloid precursor protein C-terminal fragments
(APP-CTFs) and Abeta clearance. J Biol Chem
2010;285:22091–102.100. Zandl-Lang M, Fanaee-Danesh E, Sun Y, et al.
Regulatory effects of simvastatin and apoJ on APP
processing and amyloid-beta clearance in blood-
brain barrier endothelial cells. Biochim Biophys
Acta Mol Cell Biol Lipids 2018;1863:40–60.
101. Zou K, Yamaguchi H, Akatsu H, et al. Angio-
tensin-converting enzyme converts amyloid beta-
protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its
inhibition enhances brain Abeta deposition.
J Neurosci 2007;27:8628–35.
102. Wang J, Zhao Z, Lin E, et al. Unintended ef-
fects of cardiovascular drugs on the pathogenesis
of Alzheimer’s disease. PLoS One 2013;8:e65232.
103. Regenold WT, Blumenthal JB, Loreck DJ,
et al. Elevated plasma Abeta42 in cognitively
impaired individuals taking ACE inhibitor antihy-
pertensives. Am J Alzheimers Dis Other Demen
2017;32:347–52.
104. Drews HJ, Yenkoyan K, Lourhmati A, et al.
Intranasal losartan decreases perivascular beta
amyloid, inflammation, and the decline of neuro-
genesis in hypertensive rats. Neurotherapeutics
2019;16:725–40.
105. Takeda S, Sato N, Takeuchi D, et al. Angio-
tensin receptor blocker prevented beta-amyloid-
induced cognitive impairment associated with re-
covery of neurovascular coupling. Hypertension
2009;54:1345–52.
106. Zhao W, Wang J, Ho L, Ono K, Teplow DB,
Pasinetti GM. Identification of antihypertensive
drugs which inhibit amyloid-beta protein oligo-
merization. J Alzheimers Dis 2009;16:49–57.
107. Nation DA, Ho J, Yew B. for the Alzheimer’s
Disease Neuroimaging Initiative. Older adults tak-
ing AT1-receptor blockers exhibit reduced cerebral
amyloid retention. J Alzheimers Dis 2016;50:
779–89.
108. Langenickel TH, Tsubouchi C,
Ayalasomayajula S, et al. The effect of LCZ696
(sacubitril/valsartan) on amyloid-beta concentra-
tions in cerebrospinal fluid in healthy subjects. Br J
Clin Pharmacol 2016;81:878–90.
109. Yu NN, Wang XX, Yu JT, et al. Blocking
beta2-adrenergic receptor attenuates acute
stress-induced amyloid beta peptides production.
Brain Res 2010;1317:305–10.
110. Dobarro M, Orejana L, Aguirre N, Ramirez MJ.
Propranolol restores cognitive deficits and im-
proves amyloid and Tau pathologies in a
senescence-accelerated mouse model. Neuro-
pharmacology 2013;64:137–44.
111. Liu J, Wang M. Carvedilol protection against
endogenous Abeta-induced neurotoxicity in N2a
cells. Cell Stress Chaperones 2018;23:695–702.112. Paris D, Bachmeier C, Patel N, et al. Selective
antihypertensive dihydropyridines lower Abeta
accumulation by targeting both the production
and the clearance of Abeta across the blood-brain
barrier. Mol Med 2011;17:149–62.
113. Lovell MA, Abner E, Kryscio R, Xu L, Fister SX,
Lynn BC. Calcium channel blockers, progression to
dementia, and effects on amyloid beta peptide pro-
duction. Oxid Med Cell Longev 2015;2015:787805.
114. Kitaguchi N, Tatebe H, Sakai K, et al. Influx of
tau and amyloid-beta proteins into the blood
during hemodialysis as a therapeutic extracorpo-
real blood amyloid-beta removal system for Alz-
heimer’s disease. J Alzheimers Dis 2019;69:
687–707.
115. Tholen S, Schmaderer C, Chmielewski S, et al.
Reduction of Amyloid-beta plasma levels by he-
modialysis: an anti-amyloid treatment strategy?
J Alzheimers Dis 2016;50:791–6.
116. Kitaguchi N, Hasegawa M, Ito S, et al.
A prospective study on blood Abeta levels and the
cognitive function of patients with hemodialysis: a
potential therapeutic strategy for Alzheimer’s
disease. J Neural Transm 2015;122:1593–607.
117. Liu YH, Xiang Y, Wang YR, et al. Association
between serum amyloid-beta and renal functions:
implications for roles of kidney in amyloid-beta
clearance. Mol Neurobiol 2015;52:115–9.
118. Jin WS, Shen LL, Bu XL, et al. Peritoneal
dialysis reduces amyloid-beta plasma levels in
humans and attenuates Alzheimer-associated
phenotypes in an APP/PS1 mouse model. Acta
Neuropathol 2017;134:207–20.
KEY WORDS Alzheimer’s disease, amyloid-
beta, amyloid precursor protein,
atherosclerosis, cardiovascular disease,
cardiovascular therapy, cerebral amyloid
angiopathy, coronary artery disease,
endothelial cells, leukocytes, platelets,
prognosis, vascular dementia, vascular
stiffness
APPENDIX For an expanded Methods section
and supplemental tables, please see the online
version of this paper.
Go to http://www.acc.org/
jacc-journals-cme to take
the CME/MOC/ECME quiz
for this article.
